Crinetics Pharmaceuticals IncNASDAQ:CRNX
- LAST PRICE50.8900
- TODAY'S CHANGE (%)0.3100 (0.6129%)
- Bid / Lots50.8800/ 1
- Ask / Lots50.9600/ 4
- Open / Previous Close51.2300 / 50.5800
- Day Range
- 52 Week Range
- Volume204,152
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | CRNX |
|---|---|---|
| 09:32 ET | 3610 | 51.01 |
| 09:34 ET | 400 | 50.45 |
| 09:36 ET | 100 | 50.51 |
| 09:38 ET | 874 | 50.44 |
| 09:39 ET | 200 | 50.65 |
| 09:41 ET | 200 | 50.88 |
| 09:43 ET | 905 | 50.895 |
| 09:45 ET | 300 | 51.145 |
| 09:48 ET | 7166 | 51.095 |
| 09:50 ET | 414 | 50.98 |
| 09:52 ET | 354 | 50.8 |
| 09:54 ET | 100 | 50.785 |
| 09:56 ET | 100 | 50.75 |
| 09:59 ET | 400 | 50.47 |
| 10:01 ET | 1452 | 50.49 |
| 10:06 ET | 500 | 50.4531 |
| 10:08 ET | 387 | 50.79 |
| 10:10 ET | 100 | 50.45 |
| 10:12 ET | 100 | 50.45 |
| 10:14 ET | 1000 | 50.46 |
| 10:15 ET | 1085 | 50.36 |
| 10:17 ET | 709 | 50.52 |
| 10:19 ET | 300 | 50.475 |
| 10:21 ET | 1112 | 50.47 |
| 10:24 ET | 400 | 50.41 |
| 10:26 ET | 400 | 50.53 |
| 10:28 ET | 100 | 50.5808 |
| 10:30 ET | 100 | 50.48 |
| 10:32 ET | 1700 | 50.52 |
| 10:33 ET | 400 | 50.53 |
| 10:35 ET | 410 | 50.49 |
| 10:37 ET | 200 | 50.55 |
| 10:39 ET | 1600 | 50.685 |
| 10:42 ET | 300 | 50.675 |
| 10:44 ET | 814 | 50.76 |
| 10:46 ET | 878 | 50.92 |
| 10:48 ET | 500 | 50.9 |
| 10:51 ET | 300 | 51.03 |
| 10:53 ET | 800 | 50.96 |
| 10:55 ET | 110 | 50.89 |
| 10:57 ET | 914 | 50.78 |
| 11:00 ET | 806 | 50.83 |
| 11:02 ET | 1409 | 50.98 |
| 11:04 ET | 400 | 50.885 |
| 11:06 ET | 599 | 50.875 |
| 11:08 ET | 300 | 50.87 |
| 11:11 ET | 700 | 50.9 |
| 11:13 ET | 1256 | 50.91 |
| 11:15 ET | 564 | 50.9 |
| 11:18 ET | 400 | 50.92 |
| 11:20 ET | 100 | 50.9 |
| 11:22 ET | 708 | 50.7 |
| 11:24 ET | 900 | 50.77 |
| 11:26 ET | 378 | 50.77 |
| 11:27 ET | 382 | 50.725 |
| 11:31 ET | 946 | 50.76 |
| 11:33 ET | 607 | 50.805 |
| 11:36 ET | 500 | 50.955 |
| 11:38 ET | 369 | 50.79 |
| 11:40 ET | 409 | 50.79 |
| 11:42 ET | 2434 | 50.885 |
| 11:44 ET | 200 | 50.99 |
| 11:45 ET | 200 | 50.9 |
| 11:47 ET | 289 | 50.93 |
| 11:51 ET | 400 | 50.88 |
| 11:56 ET | 100 | 50.905 |
| 11:58 ET | 800 | 50.99 |
| 12:00 ET | 400 | 50.95 |
| 12:02 ET | 100 | 50.9 |
| 12:03 ET | 200 | 50.9 |
| 12:05 ET | 900 | 50.84 |
| 12:07 ET | 2684 | 50.86 |
| 12:12 ET | 7732 | 50.74 |
| 12:14 ET | 100 | 50.735 |
| 12:16 ET | 600 | 50.83 |
| 12:18 ET | 100 | 50.83 |
| 12:20 ET | 222 | 50.765 |
| 12:21 ET | 103 | 50.7144 |
| 12:23 ET | 200 | 50.71 |
| 12:27 ET | 592 | 50.68 |
| 12:30 ET | 336 | 50.67 |
| 12:32 ET | 500 | 50.61 |
| 12:34 ET | 2967 | 50.7 |
| 12:36 ET | 200 | 50.695 |
| 12:39 ET | 1123 | 50.75 |
| 12:41 ET | 100 | 50.72 |
| 12:45 ET | 300 | 50.6545 |
| 12:48 ET | 200 | 50.63 |
| 12:52 ET | 200 | 50.7 |
| 12:56 ET | 500 | 50.72 |
| 12:57 ET | 400 | 50.69 |
| 01:01 ET | 500 | 50.785 |
| 01:06 ET | 200 | 50.85 |
| 01:08 ET | 100 | 50.78 |
| 01:10 ET | 981 | 50.81 |
| 01:14 ET | 600 | 50.78 |
| 01:17 ET | 1642 | 50.87 |
| 01:19 ET | 200 | 50.855 |
| 01:21 ET | 300 | 50.84 |
| 01:24 ET | 108 | 50.87 |
| 01:26 ET | 1224 | 51.08 |
| 01:28 ET | 332 | 51.09 |
| 01:30 ET | 400 | 51.1 |
| 01:32 ET | 1461 | 51.07 |
| 01:33 ET | 269 | 51.205 |
| 01:37 ET | 200 | 51.17 |
| 01:39 ET | 200 | 51.11 |
| 01:42 ET | 300 | 51.15 |
| 01:44 ET | 221 | 51.23 |
| 01:46 ET | 100 | 51.18 |
| 01:51 ET | 120 | 51.295 |
| 01:53 ET | 200 | 51.35 |
| 01:55 ET | 645 | 51.31 |
| 01:57 ET | 204 | 51.24 |
| 02:00 ET | 557 | 51.225 |
| 02:02 ET | 800 | 51.15 |
| 02:04 ET | 200 | 51.14 |
| 02:08 ET | 300 | 51.14 |
| 02:09 ET | 300 | 51.14 |
| 02:11 ET | 100 | 51.15 |
| 02:13 ET | 3757 | 51.14 |
| 02:15 ET | 673 | 51.14 |
| 02:18 ET | 515 | 51.18 |
| 02:20 ET | 325 | 51.1 |
| 02:24 ET | 200 | 51.03 |
| 02:26 ET | 506 | 50.99 |
| 02:27 ET | 908 | 50.83 |
| 02:29 ET | 913 | 50.85 |
| 02:31 ET | 100 | 50.75 |
| 02:33 ET | 17062 | 51.02 |
| 02:36 ET | 408 | 50.95 |
| 02:38 ET | 222 | 50.94 |
| 02:40 ET | 100 | 50.945 |
| 02:42 ET | 200 | 50.995 |
| 02:44 ET | 550 | 51.025 |
| 02:45 ET | 200 | 50.96 |
| 02:47 ET | 931 | 51.03 |
| 02:51 ET | 715 | 51.045 |
| 02:54 ET | 200 | 51.01 |
| 02:56 ET | 100 | 51.035 |
| 02:58 ET | 800 | 51.01 |
| 03:00 ET | 1173 | 51.01 |
| 03:02 ET | 600 | 51.005 |
| 03:03 ET | 100 | 50.99 |
| 03:05 ET | 215 | 50.92 |
| 03:07 ET | 100 | 50.97 |
| 03:09 ET | 400 | 50.94 |
| 03:12 ET | 478 | 50.92 |
| 03:14 ET | 1750 | 50.94 |
| 03:16 ET | 435 | 50.965 |
| 03:18 ET | 300 | 50.9 |
| 03:20 ET | 400 | 50.895 |
| 03:21 ET | 400 | 50.84 |
| 03:23 ET | 200 | 50.96 |
| 03:25 ET | 600 | 50.935 |
| 03:27 ET | 100 | 50.93 |
| 03:30 ET | 700 | 51.03 |
| 03:32 ET | 1207 | 50.89 |
Today
Yesterday
Sep 16, 2024
DJ Crinetics Pharmaceuticals Price Target Maintained With a $90.00/Share by Cantor Fitzgerald, from 11:46AM ET on Monday Sep 16, 2024 by Dow Jones
11:46AM ET on Monday Sep 16, 2024 by Dow Jones
Sep 10, 2024
Crinetics Pharmaceuticals Announces September 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4), from 4:40PM ET on Tuesday Sep 10, 2024 by Dow Jones
4:40PM ET on Tuesday Sep 10, 2024 by Dow Jones
Aug 29, 2024
Crinetics Pharmaceuticals to Participate in Two Upcoming Investor Conferences, from 4:05PM ET on Thursday Aug 29, 2024 by Dow Jones
4:05PM ET on Thursday Aug 29, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Crinetics Pharmaceuticals Inc | 4.0B | -13.5x | --- |
Immunovant Inc | 4.1B | -14.6x | --- |
BridgeBio Pharma Inc | 4.6B | -9.5x | --- |
Dyne Therapeutics Inc | 3.5B | -9.5x | --- |
Madrigal Pharmaceuticals Inc | 4.6B | -8.4x | --- |
Apogee Therapeutics Inc | 3.4B | -25.7x | --- |
Company Information
Crinetics Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its Paltusotine, an investigational, oral somatostatin receptor type 2 (SST2) agonist, is in Phase 3 clinical development for acromegaly and Phase 2 clinical development for carcinoid syndrome associated with neuroendocrine tumors. It has demonstrated pharmacologic proof-of-concept in a Phase 1 clinical study for CRN04894, an investigational, oral ACTH antagonist, that is in Phase 2 clinical studies for the treatment of congenital adrenal hyperplasia and Cushing's disease. Its drug candidates are orally delivered, small molecule new chemical entities resulting from in-house drug discovery efforts, including other programs addressing a variety of endocrine conditions such as hyperparathyroidism, polycystic kidney disease, Graves' disease, thyroid eye disease, diabetes and obesity.
Contact Information
- Headquarters
- 10222 Barnes Canyon Rd Bldg 2SAN DIEGO, CA, United States 92121-2711
- Phone
- 858-450-6464
- Fax
- 302-636-5454
Executives
- Independent Chairman of the Board
- Wendell Wierenga
- President, Chief Executive Officer, Co-Founder, Director
- R. Scott Struthers
- Co-Founder, Chief Scientific Officer
- Stephen Betz
- Chief Financial Officer
- Marc Wilson
- Chief Operating Officer
- Jeff Knight
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $4.0B |
|---|---|
Revenue (TTM) | $1.4M |
Shares Outstanding | 80.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.64 |
EPS | $-3.77 |
Book Value | $7.91 |
P/E Ratio | -13.5x |
Price/Sales (TTM) | 2,922.9 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -20,068.38% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
